Oligonucleotide Senotherapeutics
Age-related diseases (unspecified)
PreclinicalActive
Key Facts
About Senisca
Senisca is a pioneering biotech focused on a novel target in the ageing space: dysregulated RNA splicing as a driver of cellular senescence. Leveraging over 15 years of foundational academic research, the company is developing oligonucleotide-based therapeutics designed to reset splicing factor levels and effectively 'rejuvenate' senescent cells. This approach positions Senisca to address the root cause of multiple age-related diseases, moving beyond merely clearing senescent cells. With a seasoned leadership team and a proprietary platform, the company is advancing its pipeline through preclinical development.
View full company profile